CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

France's Ramsay Sante's Q1 revenue rises on French hospital admissions, Nordic strength

By Reuters News


Overview

  • France-based private hospital operator's Q1 revenue rose 2.9% yr/yr on higher French hospital admissions and Nordic strength

  • Q1 EBITDA increased 7.5%, outpacing revenue growth due to operational improvements and cost control

  • Q1 net loss narrowed from prior year


Outlook

  • Company expects FY 2027 revenue growth between 2.0% and 3.0% and stable EBITDA margin

  • Company targets FY 2029 revenue growth of about 3.0% per year and gradual EBITDA margin improvement

  • Ramsay Santé expects gross capex at about 4.0% of revenue on average over FY 2027-2029 period


Result Drivers

  • ADMISSIONS AND NORDIC GROWTH - Co said Q1 revenue was driven by higher French hospital admissions, day medicine care development, Nordic strength and St Göran contract

  • COST CONTROL - Co said strengthened productivity and cost-control initiatives offset inflation and improved EBITDA margin


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

EUR 1.23 bln

Q1 Net Loss

EUR 35.5 mln

Q1 EBITDA

EUR 120.7 mln


Analyst Coverage

  • The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 4 - Sweden's Medicover Q3 profit rises 29% on price adjustments and wider network; to focus on Europe

  • Nov 4 - Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.